Latest

FXS

Home FXS

FXS

Pharmacological Strategy Can Alleviate Multiple Behavioral and Cellular Deficiencies in a...

July 14, 2018

Research Reveals Structural Forces are Biggest Patient Impediment to Clinical Trial Participation

February 21, 2019

The Mark Foundation Funds 14 Cancer Research Projects

February 21, 2019

Vanderbilt Team Develops New Drug Synergy Algorithm for Melanoma & Lung Cancer

February 21, 2019

University of Laval Experimental ALS Therapy Utilizes Antibodies to Target TDP-43

February 20, 2019

TrialSite News is the only digital media dedicated 100% to transparent and open coverage of clinical research trial sites around the globe. Based in the Silicon Slopes in downtown Salt Lake City, Utah, we are founded by a team of experts in the clinical trials industry and dedicated to transparency, quality and clinical trial innovation.

307 West 200 South #5002
Salt Lake City, UT 84101
Contact us: admin@trialsitenews.com

Privacy Policy

Contact

© TrialSite News, Inc. All Rights Reserved

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok

Edit with Live CSS

Save
Write CSS OR LESS and hit save. CTRL + SPACE for auto-complete.

Pharmacological Strategy Can Alleviate Multiple Behavioral and Cellular Deficiencies in a...

EDITOR PICKS

Research Reveals Structural Forces are Biggest Patient Impediment to Clinical Trial Participation

The Mark Foundation Funds 14 Cancer Research Projects

Vanderbilt Team Develops New Drug Synergy Algorithm for Melanoma & Lung Cancer

University of Laval Experimental ALS Therapy Utilizes Antibodies to Target TDP-43